Recovery and Resilience Fund

Verisfield is active and strategically invests in the Research and Development of innovative pharmaceutical products that meet both the modern therapeutic needs of the market and the modern regulatory requirements. Through investment in research, the company enhances its ability to develop high value-added products, expands its portfolio and expands its competitiveness in domestic and international markets.
In the framework of the action “Reform of the Clawback system and its offsetting with research and investment costs” of the Recovery and Resilience Fund” GREECE 2.0 with funding from the European Union – NextGenerationEU, the company implemented the following research projects in the period 2022-2025:
 
TAC1-0501402: “RESEARCH AND DEVELOPMENT OF NEW PHARMACEUTICAL PRODUCTS WITH IN-VIVO CLINICAL STUDIES”
Development of pharmaceutical products with innovative formulations, which require clinical in-vivo studies to document their safety, efficacy and therapeutic value.
Budget: 5.946.240,60€
EU Funding: €3.567.744,36
 
TAC1-0481692: “RESEARCH AND DEVELOPMENT OF NEW MEDICINAL PRODUCTS WITH IN-VITRO STUDIES”
Development of innovative pharmaceutical products, approved with specialized in-vitro studies to evaluate critical characteristics of quality, performance and biopharmaceutical behavior.
Budget: 3.665.226,40€
EU Funding: €2.199.135,84
 
TAC1-0481693: “RESEARCH AND DEVELOPMENT OF NEW PHARMACEUTICAL PRODUCTS WITH SPECIAL PRODUCTION AND ANALYTICAL REQUIREMENTS”
Development of products in innovative and modern pharmaceutical forms that require specialized technological approaches, advanced analytical methods and complex development processes.
Budget: 1.793.384,00€
EU funding: €1.076.030,40
 
TAC3-0561524: “RESEARCH AND DEVELOPMENT OF NEW PHARMACEUTICAL PRODUCTS OF LOCAL APPLICATION”
Design and development of topical pharmaceutical preparations with unique characteristics, with the aim of optimizing therapeutic action and patient compliance.
Budget: 3.957.380,82€
EU funding: €2.374.428,49
 
TAC3-0561523: “RESEARCH AND DEVELOPMENT OF NEW ORAL MEDICINAL PRODUCTS”
Development of new oral pharmaceutical products with a focus on improving bioavailability, stability and therapeutic efficacy.
Budget: 4.966.626,17€
EU Funding: €2.979.975,70